Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

3'-Hydroxyesorubicin halogenated at C-2'.

W Priebe1, N Neamati, R Perez-soler

  • 1University of Texas M. D. Anderson Cancer Center, Houston 77030.

The Journal of Antibiotics
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents.

International journal of molecular sciences·2020
Same author

Curcumin as tyrosine kinase inhibitor in cancer treatment.

European journal of medicinal chemistry·2019
Same author

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

Expert opinion on pharmacotherapy·2017
Same author

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.

British journal of cancer·2015
Same author

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Intrinsic cytotoxicity and reversal of multidrug-resistance by monensin in kb parent and mdr cells.

International journal of oncology·2011

Researchers synthesized novel 2'-iodo-3'-hydroxyesorubicin analogues with potential anticancer properties. One analogue demonstrated potent in vitro cytotoxic and in vivo antitumor activity against leukemia.

Area of Science:

  • Medicinal Chemistry
  • Organic Synthesis
  • Pharmacology

Background:

  • Anthracyclines like daunorubicin and doxorubicin are crucial chemotherapy agents.
  • Modifications to anthracycline structure are explored to enhance efficacy and reduce toxicity.
  • The 2'-position and 3'-hydroxyl group are key sites for structural alteration.

Purpose of the Study:

  • To synthesize novel 3'-deamino-3'-hydroxy-2'-iodoesorubicin analogues.
  • To evaluate the cytotoxic and antitumor activities of these new compounds.
  • To explore structure-activity relationships of modified anthracyclines.

Main Methods:

  • Synthesis initiated from optically active 4,6-dideoxyhex-1-enitol.
  • Direct coupling of daunomycinone and adriamycinone derivatives with a glycal using N-iodosuccinimide.

Related Experiment Videos

  • Deprotection steps to yield the final iodinated analogues.

    • Main Results:

    • Successfully synthesized 2'-iodinated, 4'-deoxy-3'-hydroxy congeners of daunorubicin and doxorubicin.
    • Compound 14 (2'-Iodo-3'-hydroxyesorubicin) exhibited in vitro cytotoxic activity comparable to doxorubicin.
    • Compound 14 demonstrated superior in vivo antitumor activity against L-1210 leukemia compared to doxorubicin.

    Conclusions:

    • The synthesized 2'-iodo-3'-hydroxyesorubicin analogues represent promising new anticancer drug candidates.
    • The introduction of a 2'-iodo group and modification at the 3'-hydroxyl position can enhance antitumor potency.
    • Further investigation into these analogues may lead to improved chemotherapeutic agents.